Search Technologies
Displaying 71 - 80 of 225 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
A Method for Monitoring Cancer and for Regulation of Semaphorin 4D to Improve Cancer Immunotherapy Regimens
Published Monday, May 14, 2018The efficacy of current cancer immunotherapies has been limited by the response of immunosuppressive elements such as myeloid derived suppressor cells (MDSC) and T regulatory cells. Understanding the mechanism behind the suppression of antitumor immunity, and finding ways to revert it, should lead to improved cancer immunotherapy outcomes....
Investigator(s): Rania Younis
Categories: Diagnostics, Biomarker, Therapeutics
Keyword(s): Semaphorin 4D, immunotherapy, oncology, head and neck, cancer
Docket: RY-2015-129
-
Proton Arc Therapy with Modulating Proton Energies
Published Tuesday, May 1, 2018Proton radiation therapy is a type of external beam radiotherapy that uses the energy distribution of protons to irradiate unwanted and diseased tissues. The proton beam can be directed and deposited by a physician in a designated 3-dimensional tissue volume with greater control and accuracy than traditional radiation...
Investigator(s): Byong Yong Yi, Ulrich Langner, Warren D’Souza
Categories: Devices, Imaging devices, Therapeutics
Keyword(s): Radiation Oncology, imaging
Docket: BY-2017-075
-
Generation of a Biomarker Kit with Prognostic Capability for Metastatic Breast Cancer
Published Monday, March 12, 2018Obscurins are a family of giant cytoskeletal proteins primarily localized at cell-cell junctions of breast epithelial cells. While abundantly expressed in healthy breast epithelial tissue, their expression is dramatically decreased in tissue from advanced stage breast cancer biopsies (grade 2 or higher) compared to matched normal samples....
Investigator(s): Aikaterini Kontrogiani-Konstantopoulos
Categories: Biomarker
Keyword(s): Diagnostics, Molecular biology, biomarker
Docket: AK-2016-131
-
Small Molecule Lipid II Inhibitors
Published Friday, February 16, 2018Drug resistance in microorganisms is an urgent and growing concern as more and more microorganisms are found with resistance to commonly used treatments. For bacterial infections alone, approximately 2 million people are infected a year and 23,000 deaths can be directly correlated to drug-resistant bacteria (CDC). There is an urgent need for...
Investigator(s): Eric DeLeeuw, Jamal Chauhan, Steven Fletcher, Alexander MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): Anti-infective
Docket: ED-2016-042
-
Hyper-glycosylated Antibodies with Selective Fc Receptor Binding
Published Friday, February 16, 2018This technology is a set of hyper-glycosylated antibodies that have been modified in the Fc domain of the antibody to either enhance or reduce the affinity of the Fc region to the Fc γ...
Investigator(s): Eric Sundberg, Beatriz Trastoy-Bello
Categories: Therapeutics, Biologics
Keyword(s): Immunology
Docket: ES-2013-128
-
Giant obscurins and their uses in cancer prognosis and therapy
Published Wednesday, February 7, 2018Approximately 20% of cancer patients diagnosed annually in the US have metastatic cancer, which is associated with much poorer prognoses compared to patients with localized disease. Accurately determining which patients are at risk of developing metastases is a major clinical challenge. Giant obscurins, encoded by the single obscn gene, are...
Investigator(s): Aikaterini Kontrogianni-Konstantopoulos, Konstantinos Konstantopoulos, Marey Shriver, Nicole Perry
Categories: Biomarker, Therapeutics, Biologics
Keyword(s): oncology, antibody
Docket: AK-2013-059
-
Stable Immunogen Based on Inner Domain of HIV-1 GP120 for Inducing Immunity Against HIV
Published Monday, February 5, 2018Antiviral therapy and prevention strategies have made a tremendous impact on the spread of Human Immunodeficiency Virus (HIV-1). However, an HIV vaccine is highly sought after to treat and prevent HIV. This technology is a set of stable protein immunogens comprised of portions of the inner domain of the HIV-1 gp120 protein for potential...
Investigator(s): Marzena Pazgier, William Tolbert, Neelakshi Gohain, George Lewis
Categories: Vaccines
Keyword(s): vaccine, HIV
Docket: MP-2014-131
-
Protective Vaccine & Diagnostic for Acinetobacter baumannii Infection
Published Thursday, February 1, 2018Bacterial infections often persist due to the formation of protective biofilms, which reduce the effectiveness of antimicrobial agents and immune effectors. Acinetobacter baumannii (A. baumannii) is an opportunistic, gram-negative bacteria that is associated with infections in health care settings and...
Investigator(s): Mark Shirtliff, Janette Harro
Keyword(s): vaccine, diagnostic
Docket: MS-2017-032
-
Small molecule inhibitors of the Mcl-1 oncoprotein based on a 1-hydroxy-2-naphthoate scaffold
Published Monday, January 29, 2018Myeloid cell leukemia-1 (Mcl-1) is an oncoprotein over-expressed in multiple human cancers and is responsible for resistance to conventional anti-cancer agents. An anti-apoptotic member of the Bcl-2 protein family, Mcl-1 plays a major role in the homeostasis of cell proliferation and cell death. The cell-killing function of the pro-apoptotic...
Investigator(s): Steven Fletcher, Maryanna Lanning, Lijia Chen
Categories: Therapeutics, Small molecules
Keyword(s): oncology
Docket: SF-2014-103
-
Anthrax toxin protective antigen proteins engineered to target membrane-anchored serine proteases overexpressed on tumor cells
Published Friday, January 26, 2018Bacillus anthracis is the bacterium that produces the anthrax toxin, which consists of the three distinct proteins protective antigen (PrAg), lethal factor (LF), and edema factor (EF). In order for the toxin to be activated, the PrAg moiety of the toxin must bind to cell-surface proteins and become proteolytically cleaved by the proprotein...
Investigator(s): Toni Antalis, Erik Martin
Categories: Therapeutics, Biologics
Keyword(s): oncology, protein therapy, anthraz, ZMT
Docket: TA-2016-015